[go: up one dir, main page]

WO1999005266B1 - Transfert de noyau entre des especes differentes - Google Patents

Transfert de noyau entre des especes differentes

Info

Publication number
WO1999005266B1
WO1999005266B1 PCT/US1998/015387 US9815387W WO9905266B1 WO 1999005266 B1 WO1999005266 B1 WO 1999005266B1 US 9815387 W US9815387 W US 9815387W WO 9905266 B1 WO9905266 B1 WO 9905266B1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
nuclear transfer
donor
hours
enucleated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/015387
Other languages
English (en)
Other versions
WO1999005266A3 (fr
WO1999005266A2 (fr
Inventor
Neal L First
Tanja Dominko
Maissam Mitalipoua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Priority to AU85875/98A priority Critical patent/AU8587598A/en
Publication of WO1999005266A2 publication Critical patent/WO1999005266A2/fr
Publication of WO1999005266A3 publication Critical patent/WO1999005266A3/fr
Publication of WO1999005266B1 publication Critical patent/WO1999005266B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8771—Bovine embryos

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

On décrit un procédé permettant de produire des embryons clonés par transfert nucléaire à partir de cellules donneuses différenciées. Le procédé consiste à cultiver des cellules donneuses différenciées dans un milieu pauvre en sérum et à utiliser en tant qu'ovocyte récepteur des ovocytes de bovins pour des cellules donneuses provenant d'espèces différentes. On peut utiliser ce procédé pour produire des animaux génétiquement identiques et des animaux transgéniques.
PCT/US1998/015387 1997-07-26 1998-07-24 Transfert de noyau entre des especes differentes Ceased WO1999005266A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU85875/98A AU8587598A (en) 1997-07-26 1998-07-24 Trans-species nuclear transfer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5310397P 1997-07-26 1997-07-26
US60/053,103 1997-07-26

Publications (3)

Publication Number Publication Date
WO1999005266A2 WO1999005266A2 (fr) 1999-02-04
WO1999005266A3 WO1999005266A3 (fr) 1999-04-15
WO1999005266B1 true WO1999005266B1 (fr) 1999-09-23

Family

ID=21981947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/015387 Ceased WO1999005266A2 (fr) 1997-07-26 1998-07-24 Transfert de noyau entre des especes differentes

Country Status (2)

Country Link
AU (1) AU8587598A (fr)
WO (1) WO1999005266A2 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9517780D0 (en) * 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
BR9711204A (pt) * 1996-08-19 1999-08-17 Univ Massachusetts Linhagens de c-lulas embriÄnicas ou similares s indiferenciadas produzidas por transplante nuclear de esp-cies hibridas
US7696404B2 (en) 1996-08-19 2010-04-13 Advanced Cell Technology, Inc. Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions
CA2323094A1 (fr) * 1998-03-02 1999-09-10 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Lignees cellulaires embryonnaires ou de type souche produites par transplantation nucleaire d'especes croisees
JP2002511234A (ja) * 1998-03-16 2002-04-16 リレグ ピーティーワイ リミテッド ブタの核移植
CN1304443A (zh) * 1999-06-30 2001-07-18 黄禹锡 一种生产克隆牛的方法
EP1196426A4 (fr) * 1999-06-30 2003-09-03 Advanced Cell Tech Inc Transfert cytoplasmique permettant de reduire la differentiation de cellules receveuses
WO2001000794A1 (fr) * 1999-06-30 2001-01-04 Hwang, Woo-Suk Procede de production de tigres clones utilisant une technique de transplantation de noyau inter-especes
WO2001000793A1 (fr) * 1999-06-30 2001-01-04 Hwang, Woo-Suk Procede d'obtention d'embryons humains clones au moyen de techniques de transplantation inter-especes de noyaux
EP1214404A4 (fr) * 1999-09-14 2003-09-03 Univ Massachusetts Lignees de cellules embryonnaires ou de type souche produites par transplantation nucleaire d'especes croisees et technique destinee a renforcer le developpement embryonnaire par modification genetique de cellules donneuses ou par culture de tissus.
EP1240318A4 (fr) * 1999-12-20 2004-12-08 Univ Massachusetts Cellules souches ou embryonnaires produites par transplantation nucleaire heterospecifique
WO2003018767A2 (fr) 2001-08-27 2003-03-06 Advanced Cell Technology, Inc. Transdifferenciation et redifferenciation de cellules somatiques et production de cellules pour therapies cellulaires
EP2302034B1 (fr) 2005-08-03 2020-10-14 Astellas Institute for Regenerative Medicine Procédés améliorés de reprogrammation des cellules somatiques animales
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
EP2986729B1 (fr) 2013-04-16 2018-09-19 Regeneron Pharmaceuticals, Inc. Modification ciblée du génome d'un rat
JP6174811B2 (ja) 2013-12-11 2017-08-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ゲノムの標的改変のための方法及び組成物
ES2975317T3 (es) 2013-12-11 2024-07-04 Regeneron Pharma Métodos y composiciones para la modificación dirigida de un genoma
CN113215196B (zh) 2014-06-06 2024-09-03 瑞泽恩制药公司 用于修饰所靶向基因座的方法和组合物
SMT201800652T1 (it) 2014-06-26 2019-01-11 Regeneron Pharma Metodi e composizioni per modificazioni genetiche mirate e metodi di utilizzo
SG11201703747RA (en) 2014-11-21 2017-06-29 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAs
KR102530821B1 (ko) 2014-12-19 2023-05-10 리제너론 파마슈티칼스 인코포레이티드 단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물
CA2978096C (fr) 2015-03-16 2022-06-28 Regeneron Pharmaceuticals, Inc. Animal non humain presentant une baisse de la fonction des neurones moteurs superieurs et inferieurs et de la perception sensorielle
EP3689139B1 (fr) 2015-05-29 2025-01-01 Regeneron Pharmaceuticals, Inc. Cellules de rongeurs comprenant une perturbation dans un locus c9orf72
SG11201806427WA (en) 2016-02-16 2018-08-30 Regeneron Pharma Non-human animals having a mutant kynureninase gene
SG10202102885UA (en) 2016-05-20 2021-05-28 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide rnas
CN109803530A (zh) 2016-07-29 2019-05-24 瑞泽恩制药公司 包含引起c-截短的原纤维蛋白-1表达的突变的小鼠
WO2018064600A1 (fr) 2016-09-30 2018-04-05 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant une expansion de répétition hexanucléotidique dans un locus c9orf72
CN110461146A (zh) 2017-02-27 2019-11-15 再生元制药公司 视网膜劈裂的非人类动物模型
US11696572B2 (en) 2017-06-27 2023-07-11 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ASGR1 locus
EP3585159B1 (fr) 2017-07-31 2025-05-14 Regeneron Pharmaceuticals, Inc. Procédé de test de la capacité d'une nucléase crispr/cas9 à modifier un locus génomique cible in vivo, en utilisant une souris ou un rat transgénique cas comprenant une cassette d'éxpression cas9 dans son genome
MX2020001177A (es) 2017-07-31 2020-09-25 Regeneron Pharma Animales no humanos reporteros de crispr y usos de los mismos.
CA3065579A1 (fr) 2017-07-31 2019-02-07 Regeneron Pharmaceuticals, Inc. Evaluation de la recombinaison induite par crispr/cas avec un acide nucleique donneur exogene in vivo
EP4276185A3 (fr) 2017-09-29 2024-02-21 Regeneron Pharmaceuticals, Inc. Rongeurs comprenant un locus ttr humanisé et procédés d'utilisation
EP3585163B1 (fr) 2017-11-10 2022-03-09 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant une mutation de slc30a8 et procédés d'utilisation
JP7361031B2 (ja) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
CN111885915B (zh) 2018-03-19 2023-04-28 瑞泽恩制药公司 使用crispr/cas系统对动物进行转录调制
CN112969367B (zh) 2018-09-13 2023-04-07 瑞泽恩制药公司 作为c3肾小球病模型的补体因子h基因敲除大鼠
SG11202105189RA (en) 2018-12-20 2021-06-29 Regeneron Pharma Nuclease-mediated repeat expansion
US11737435B2 (en) 2019-04-04 2023-08-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized coagulation factor 12 locus
AU2020286382A1 (en) 2019-06-04 2021-11-04 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use
IL288606B2 (en) 2019-06-07 2024-12-01 Regeneron Pharma Non-human animals comprising a humanized albumin locus
WO2020264339A1 (fr) 2019-06-27 2020-12-30 Regeneron Pharmaceuticals, Inc. Modélisation de la protéinopathie à tdp-43
WO2021108363A1 (fr) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Régulation à la hausse médiée par crispr/cas d'un allèle ttr humanisé
CA3169272A1 (fr) 2020-01-28 2021-08-05 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant un locus pnpla3 humanise et procedes d'utilisation
EP4099821A1 (fr) 2020-02-07 2022-12-14 Regeneron Pharmaceuticals, Inc. <smallcaps/>? ? ?klkb1? ? ? ? ?animaux non humains comprenant un locushumanisé et procédés d'utilisation
US20230102342A1 (en) 2020-03-23 2023-03-30 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
US20230232796A1 (en) 2020-06-26 2023-07-27 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ace2 locus
AU2022381205A1 (en) 2021-11-04 2024-03-28 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified cacng1 locus
KR20240117571A (ko) 2021-12-08 2024-08-01 리제너론 파마슈티칼스 인코포레이티드 돌연변이 마이오실린 질환 모델 및 이의 용도
WO2023122506A1 (fr) 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant des loci ace2 et tmprss humanisés
CN113943712B (zh) * 2021-12-20 2022-03-22 南京岚轩生物科技有限公司 一种电融合缓冲液、其制备方法及电融合方法
US20250194571A1 (en) 2022-02-07 2025-06-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for defining optimal treatment timeframes in lysosomal disease
CN118613498A (zh) 2022-02-11 2024-09-06 瑞泽恩制药公司 用于筛选4R Tau靶向剂的组合物和方法
WO2023235677A1 (fr) 2022-05-31 2023-12-07 Regeneron Pharmaceuticals, Inc. Modèle animal de protéinopathie tdp-43
EP4561348A2 (fr) 2022-07-29 2025-06-04 Regeneron Pharmaceuticals, Inc. Animaux non humains comprenant un locus de récepteur de transférrine modifié
KR20250044256A (ko) 2022-08-05 2025-03-31 리제너론 파마슈티칼스 인코포레이티드 Tdp-43의 응집 저항성 변이체
US20240224964A9 (en) 2022-09-29 2024-07-11 Regeneron Pharmaceuticals, Inc. Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
WO2024163650A1 (fr) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Animaux comprenant un locus klhdc7b modifié
WO2025006963A1 (fr) 2023-06-30 2025-01-02 Regeneron Pharmaceuticals, Inc. Procédés et compositions pour augmenter la réparation dirigée par homologie
WO2025122754A1 (fr) 2023-12-07 2025-06-12 Regeneron Pharmaceuticals, Inc. Animaux non humains knockout pour gaa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496720A (en) * 1993-02-10 1996-03-05 Susko-Parrish; Joan L. Parthenogenic oocyte activation
GB9517780D0 (en) * 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
BR9711204A (pt) * 1996-08-19 1999-08-17 Univ Massachusetts Linhagens de c-lulas embriÄnicas ou similares s indiferenciadas produzidas por transplante nuclear de esp-cies hibridas
US5945577A (en) * 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells

Also Published As

Publication number Publication date
WO1999005266A3 (fr) 1999-04-15
WO1999005266A2 (fr) 1999-02-04
AU8587598A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
WO1999005266B1 (fr) Transfert de noyau entre des especes differentes
Cheong et al. Birth of mice after transplantation of early cell-cycle-stage embryonic nuclei into enucleated oocytes
Tsunoda et al. Full‐term development of mouse blastomere nuclei transplanted into enucleated two‐cell embryos
EP0739412B1 (fr) CELLULES d&#39;ongules, SOUCHES D&#39;EMBRYONS UTILISEES COMME DONNEUSES DE NOYAUX ET PROCEDES DE TRANSFERT DE NOYAUX POUR LA PRODUCTION D&#39;ANIMAUX CHIMERIQUES ET TRANSGENIQUES
Fulka Jr et al. Nuclear transplantation in mammals: remodelling of transplanted nuclei under the influence of maturation promoting factor
Prather et al. Nuclear transplantation in the pig embryo: nuclear swelling
Kragh et al. Efficient in vitro production of porcine blastocysts by handmade cloning with a combined electrical and chemical activation
JP2001509361A5 (fr)
Kono et al. Nuclear transplantation of rat embryos
Niu et al. Distribution and content of lipid droplets and mitochondria in pig parthenogenetically activated embryos after delipation
Roh et al. Technical report: In vitro development of porcine parthenogenetic and cloned embryos: comparison of oocyte-activating techniques, various culture systems and nuclear transfer methods
First et al. Genomic potential in mammals
Smith et al. Factors affecting the viability of nuclear transplanted-embryos
Yamamoto et al. Production of mouse offspring from inactivated spermatozoa using horse PLCζ mRNA
CN1280412C (zh) 产生克隆胚胎和其子代的方法以及由所述方法生产的细胞
Renard Chromatin remodelling and nuclear reprogramming at the onset of embryonic development in mammals
Miki et al. Cytoplasmic asters are required for progression past the first cell cycle in cloned mouse embryos
Hirabayashi et al. Factors influencing chromosome condensation and development of cloned rat embryos
Haraguchi et al. Electroporation‐mediated genome editing in vitrified/warmed porcine zygotes obtained in vitro
Savy et al. Effect of embryo aggregation on in vitro development of adipose-derived mesenchymal stem cell-derived bovine clones
AU777799B2 (en) Telophase enucleated oocytes for nuclear transfer
Lu et al. Reconstruction of human embryos derived from somatic cells
Stice et al. Progress towards efficient commercial embryo cloning
AU1655895A (en) Bovine nuclear transplantation
Riaz et al. Mouse cloning and somatic cell reprogramming using electrofused blastomeres

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase in:

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09463276

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA